



# Meningococcal Vaccines Session

**Veronica McNally, JD**  
**Chair, Meningococcal Work Group**

Advisory Committee on Immunization Practices  
June 24, 2020

# Issue under consideration

- A new meningococcal serogroup A, C, W, Y (MenACWY) vaccine, MenACWY-TT (MenQuadfi), was approved by the FDA in April 2020
  - Approved in ages  $\geq 2$  years
- Determine whether MenACWY-TT should be available as an option for MenACWY vaccination **according to currently recommended dosing and schedules** in the Vaccines for Children (VFC) program

# Vote

- VFC Vote: Inclusion of MenACWY-TT as an option for meningococcal serogroup A, C, W, and Y vaccination in the Vaccines for Children program according to currently recommended dosing and schedules
- No ACIP vote as no changes to recommendations are proposed

# Meningococcal Disease is a Serious Infection



Die despite antibiotics



Survivors have long-term sequelae

Hearing loss



Created by Francesca Arena  
from Noun Project

Amputations




Created by Jafri Ali  
from Noun Project

Cognitive deficits



# Incidence of meningococcal disease – United States, 2006-2018



Source: National Notifiable Diseases Surveillance System, with additional information on serogroup from state health departments

# MenACWY vaccines in the United States

- MenACWY vaccines have been recommended for adolescents and persons at increased risk since 2005
- Three MenACWY conjugate vaccines currently available:
  - MenACWY-D (Menactra)
  - MenACWY-CRM (Menveo)
  - (**new**) MenACWY-TT (MenQuadfi)

# Populations currently recommended for MenACWY vaccination

- Adolescents: one dose at 11 or 12 years, booster at age 16 years.
- Persons aged  $\geq 2$  months at increased risk for meningococcal disease due to specified underlying conditions or exposures

# Meningococcal Vaccines Work Group Activities

- Reviewed data on MenACWY-TT safety, immunogenicity, persistence of immune response, and concomitant administration with other vaccines
- Used Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) along with Evidence to Recommendations Framework (EtR) to assess use of MenACWY-TT as an option for MenACWY vaccination.

# Agenda

- Safety and immunogenicity of MenQuadfi
  - Corey Robertson, Sanofi Pasteur
- MenACWY-TT (MenQuadfi): Evidence to Recommendations Framework (EtR), Grading of Recommendations, Assessment, Development, and Evaluation (GRADE), and Workgroup Considerations
  - Lucy McNamara, CDC/NCIRD
- Vaccines for Children (VFC) Resolution Language
  - Frank Whitlatch, CDC/NCIRD

# Work Group Members

## ACIP Members

- Veronica McNally (Chair)
- Hank Bernstein

## *Ex Officio* Members

- Lucia Lee (FDA)
- Anuja Rastogi (FDA)
- Ruth Brenner (DOD)

## CDC Work Group Lead

- Lucy McNamara (CDC/NCIRD)

## Liaison Representatives

- Nina Ahmad (AAFP)
- Oliver Baclic (NACI)
- Carol Baker (IDSA)
- Susan Even (ACHA)
- Rachel Herlihy (IAC)
- Nneka Holder (SAHM)
- Martin Luta (CSTE)
- Ruth Lynfield (AAP)
- Paul McKinney (APTR)
- William Schaffner (NFID)

## Consultants

- Mike Brady
- Kathleen Harriman
- Mary Healy
- Cody Meissner
- Paul Offit
- Lorry Rubin
- David Stephens

## CDC contributors

- Alison Albert
- Amy Blain
- Jamie Cope
- Jonathan Duffy
- LeAnne Fox
- Susan Hariri
- Andrew Kroger
- Jessica MacNeil
- Sarah Mbaeyi
- Sara Oliver
- Ismael Ortega-Sanchez
- Xin Wang
- Charnetta Williams
- JoEllen Wolicki

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

